Neurology

Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent company of Axovant – Roivant, licensed 5HT2A inverse serotonin receptor agonist nelotanserin from Arena Pharmaceuticals for USD 4 million upfront in 2015 and initiated midphase trials of the drug in patients with dementia with Lewy bodies (DLB) and Parkinson’s disease dementia. CRISPR-based heart test identifies genetic risk for severe cardiomyopathy A dangerous...